Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based Founder operating in the Pharmaceutical space. If you think a Founder is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Furquan Kidwai
Founder & CEO of Dawaai
Furquan Kidwai is an entrepreneur building a pharmacy for emerging Asia. Prior to this journey, Kidwai was an investment banker for over eight years in London where, in his last role, he was the Head of CEEMEA Financing as well as a Senior Vice President in the Fixed Income business at the Royal Bank of Scotland. Before joining RBS, Mr. Kidwai worked at Merrill Lynch and Lehman Brothers in their London and New York offices. Mr. Kidwai has a Master’s degree in International Relations from Cambridge University. He also holds an MSc in Financial Engineering & Risk Management from Imperial College London and BEng (Hons) in Electrical and Computer Engineering from the University of Bristol.
Follow Furquan Kidwai:
About Dawaai: Dawaai operates as a digital health platform with an online network of pharmacies and generic medicine.
Michael Anstey
Co-Founder and Chief Operating Officer of Proteorex Therapeutics Inc.
Michael Anstey is an Investment Director specialising in healthcare investments. Before joining CIC he was a Principal in the Healthcare Practice Area at The Boston Consulting Group’s (BCG) Toronto office. Michael has experience in advising multinational healthcare businesses across North America, Europe, India, and Japan on a broad range of topics, including corporate strategy, sales and marketing, new launches, R&D and medical strategy, and M&A. Michael was co-founder and COO of an early stage biotechnology company focused on developing small molecule drugs that target protein-protein interactions implicated in disease. Prior to BCG, Michael worked in venture capital, where he focused on investing in early stage healthcare and life science businesses. Michael earned his DPhil in Zoology in the field of neurobiology, jointly supervised by professors at the University of Cambridge and the University of Oxford. Michael sits on the board of Bicycle Therapeutics.
Follow Michael Anstey:
About Cambridge Innovation Capital, Proteorex Therapeutics Inc.: Expanding horizons to find cures
Sebastian Brunemeier
Founder & COO of Samsara Therapeutics
Sebastian Brunemeier is the Founder and COO of Samsara Therapeutics.
Follow Sebastian Brunemeier:
About Cyclone Therapeutics, Samsara Therapeutics, U.S. Department of State, University of Oxford: Samsara Therapeutics is a biopharmaceutical company that aims to discover therapeutics to treat rare genetic and neurodegenerative disease.
Charles Blundell
Founder & CTO of C4X Discovery
Charles invented C4XD’s core Conformetrix technology, founded the Company and led the spin-out from The University of Manchester in 2008 with Dr. Andrew Almond. Charles has been awarded multiple grants from top UK research councils during his career and has published over 20 research articles in leading scientific journals. He studied for his undergraduate masters degree and DPhil in Biochemistry at the University of Oxford (Keble College), graduating within the top 5 of his peer group.
Follow Charles Blundell:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
Maria Chatzou Dunford
CEO and Co-Founder of Lifebit
Dr. Maria Chatzou, CEO of Lifebit, is a biotech innovator and a proud geek, expert in bioinformatics, medical informatics and high performance computing. She is also a passionate entrepreneur and has founded two companies, Innovation Forum Barcelona and Techstars-backed Lifebit. Prior to Lifebit, she was a researcher at the Centre for Genomic Regulation, in Barcelona, where she was designing and deploying tools and methods that facilitate the analysis of Big Biomedical Data, allow for biological discoveries, and promote personalised medicine. She was part of the developing team of Nextflow, a programming framework that is revolutionising the computational analysis of genomic data and setting the foundations for personalised medicine computational analyses. Maria is also a frequent industry speaker and has spoken in many international conferences on the subjects of docker containers, genomics workflows, the computational challenges of personalised medicine, AI and HPC in genomics, women in leadership, entrepreneurship, science ventures, among many other topics.
Follow Maria Chatzou Dunford:
About Lifebit: Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Pablo Prieto Barja
CTO and Co-Founder of Lifebit
Follow Pablo Prieto Barja:
About Lifebit: Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Zhangming Niu
Founder & CEO of MindRank AI
Follow Zhangming Niu:
About MindRank AI: MindRank is a developer of an AI-enabled drug-discovery platform intended to discover and develop next generation precision medicines.
Yiannis Kiachopoulos
CEO, Co-Founder of Causaly
Follow Yiannis Kiachopoulos:
About Causaly: Causaly is teaching computers to read all knowledge in Biomedicine
Artur Saudabayev
Co-Founder, CTO of Causaly
Follow Artur Saudabayev:
About Causaly: Causaly is teaching computers to read all knowledge in Biomedicine
Barney Gilbert
Founder, Co-CEO of Pando
Barney Gilbert worked in the NHS as a doctor before founding Pando, a healthtech company working to connect everyone working in healthcare. Listed in the UK’s Disruption50 Index for 2019. Forbes 30 Under 30 alum.
Follow Barney Gilbert:
About NHS England, Pando: Forward is now Pando! Pando is an essential tool for teamwork and secure collaboration in health and social care.
Philip Mundy
Founder of Pando
London-based Philip Mundy is a co-founder and Joint CEO of Forward Health, a secure messaging platform for healthcare professionals. Philip has previously founded a series of successful startups including ‘proptech’ company Goodlord. Since 2018, Philip has also sat on NHS England’s Clinical Entrepreneur Programme as a mentor.
Follow Philip Mundy:
About Beem, Goodlord, Pando: Forward is now Pando! Pando is an essential tool for teamwork and secure collaboration in health and social care.
Lydia Yarlott
Founder, People of Pando
Follow Lydia Yarlott:
About Pando: Forward is now Pando! Pando is an essential tool for teamwork and secure collaboration in health and social care.
Vibhor Gupta
Director and Founder of Pangaea Data
Vibhor is an entrepreneur in residence at Nexgen Capital Ventures where he is involved in deal flow and leading creative technological opportunties within Life Sciences following his breadth of experience in industry and academia over the last 16 years. Prior to this role, Vibhor has served in various positions ranging from technical bioinformatics roles, sales (of software technology products) and executive management. Vibhor started and built the European business for Quantum Secure, which was an enterprise software solutions provider and was successfully acquired in 2015. Most recently he served as a Senior Vice President at Seven Bridges Genomics which provides cloud (SaaS) based bioinformatics solutions for the Life Sciences industry. Vibhor has also worked as a management and technology consultant for Deloitte. His academic career focused on bioinformatics, epigenetics and molecular biology studies in oncology and infectious diseases. Vibhor has access to an extensive network in the industry and was recently honoured as an advisor to two prominent organisations, HealthEx and FrontLine Genomics. He was also a Technology Lead on ASIS’s UK committee, which is the largest professional body for CSOs and CISOs in the world.
Follow Vibhor Gupta:
About Pangaea Data: Pangaea Data provides a machine learning-based software solution making scientific and clinical data more meaningful.
Alex Zhavoronkov
Founder & Chief Executive Officer of Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe’s largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Follow Alex Zhavoronkov:
About Deep Longevity, Insilico Medicine: Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Yue Xiong
Co-Founder and Chief Scientific Officer of Cullgen
Dr. Yue Xiong, PhD is a Director and Member of Scientific Advisory Board at Cullgen Inc. Dr. Xiong was awarded Pew Scholar Award (1995), American Cancer Society Junior Faculty Research Award (1995), AACR-Gertrude B. Elion Cancer Research Awards (1999), UNC Hettleman Award for Scholarly Achievement (1999), UNC Battle Distinguished Cancer Research Award (2011), Elected Fellow, American Association for Advancement of Science (2012). Dr. Xiong has published more than 160 research papers in peer-reviewed publication and granted two US patents. After completing a Ph.D. Postdoctoral fellowship at Cold Spring Harbor Lab, since 1993, Dr. Xiong joined Department of Biochemistry & Biophysics at University of North Carolina at Chapel Hill as a William R. Kenan Professor. Dr. Xiong finished his undergraduate at Fudan University in 1982 and Ph.D from University of Rochester in 1989.
Follow Yue Xiong:
About Cullgen: Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Jian Jin
Co-Founder of Cullgen
Follow Jian Jin:
About Cullgen, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai, Icahn School of Medicine at Mount Sinai: Cullgen is a drug discovery services intended to create new drugs for the treatment of diseases that currently lack effective therapies.
Pablo Graiver
President and Founder of Antidote.me
Pablo Graiver is Co-Founder of Antidote Technologies Ltd. (a/k/a TrialReach Ltd.) and serves as its Chief Executive Officer and Executive Director. Pablo Graiver served as Vice President of Business Development, Europe of Kayak Software Corporation. He has over 12 years of entrepreneurial and management experience in the online industry. He was an early member of NetJuice, one of the largest Internet incubators in Europe; MD at Donde Comprar.com, the first e-commerce directory in Spanish; and later co-founder and Vice President of Strategy at Kelkoo, acquired by Yahoo! in 2004. Pablo Graiver set up and launched Kayak.com in Europe, and served as European Sales Director at ValueClick (NASDAQ: VCLK). He studied Biology and Business Administration at UAM in Madrid.
Follow Pablo Graiver:
About Antidote.me: Antidote is a digital health company that accelerates and improves medical research by combining technologies, data, and business models.
Andrew Hopkins
Co-Founder and CEO of Exscientia
Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery.
Follow Andrew Hopkins:
About Exscientia, Kinetic Discovery Ltd.: Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Andrew McElroy
Co-Founder & Strategic Project Manager of Exvastat
Andrew McElroy is the CEO, Director & Founder of EligoChem & he attended University of Cambridge in 1977.
Follow Andrew McElroy:
About EligoChem, Exvastat, The Research Network: Exvastat is an innovative, preclinical-stage pharmaceutical company.
Daniel L. Cohen
CEO and Co-Founder of 3D Bio Holdings
Daniel L. Cohen is the Chief Executive Officer and Director at 3D Bio Holdings.
Follow Daniel L. Cohen:
About 3D Bio Holdings: 3D Bio Holdings is a company that specializes in regenerative medicine and devices.
Hod Lipson
Co-Founder of 3D Bio Holdings
Hod Lipson is a professor of Mechanical Engineering and Data Science at Columbia University in New York, and a co-author of the award winning book “Fabricated: The New World of 3D printing”, and “Driverless: Intelligent cars and the road ahead”, by MIT Press. Before joining Columbia University in 2015, Hod spent 14 years as a professor at Cornell University. He received his PhD in 1999 from the Technion – Israel Institute of Technology, followed by a postdoc at Brandeis University and MIT.
Follow Hod Lipson:
About 3D Bio Holdings, Columbia University: 3D Bio Holdings is a company that specializes in regenerative medicine and devices.
Agnieszka Chomka
Co-Founder and Head of R&D of BioMe Oxford
Agnieszka is an intestinal immunologist at the Kennedy Institute for Rheumatology, University of Oxford. Her main research interests focus on the microbial-host interactions in the large intestine. She was awarded the prestigious Wellcome Trust scholarship at the University of Oxford to conduct her research into the role of a tissue-resident regulatory immune cell population in the gut. Agnieszka has published her results in top peer-review research journals.
Follow Agnieszka Chomka:
About BioMe Oxford, Globe Life Sciences: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Soren Krogsgaard Thomsen
Co-Founder, CEO and Managing Director of BioMe Oxford
Soren is a medical scientist at the University of Oxford, with a background in the natural sciences and genetics research. He previously worked as a consultant for pharma and OBR consulting, and has published on his experiences as an academic entrepreneur. Soren’s current research is focused on translating large-scale genetic data into mechanisms for disease to inform new therapeutic strategies. He dreams of one day enabling similar population-wide microbiome studies using the platform technology under development at BioMe Oxford Ltd.
Follow Soren Krogsgaard Thomsen:
About BioMe Oxford, Vertex Pharmaceuticals: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Patrick Albers
Co-Founder and Head of Technology of BioMe Oxford
Follow Patrick Albers:
About BioMe Oxford, Wellcome Trust Sanger Institute: Unlocking your gut microbiome by developing a medical device for targeted and non-invasive sampling
Edward Ungar
Co-Founder & CEO of Pharmacierge
Edward Ungar is a Co-founder at Pharmacierge.
Follow Edward Ungar:
About Pharmacierge: The free e-prescribing service chosen by Private GPs and Consultants to deliver medication to their patients nationwide
Robert Ungar
Co-Founder of Pharmacierge
Robert Ungar is a Co-Founder at Pharmacierge.
Follow Robert Ungar:
About Pharmacierge: The free e-prescribing service chosen by Private GPs and Consultants to deliver medication to their patients nationwide
Loubna Bouarfa
Co-Founder & CEO of OKRA Technologies
Loubna has won several awards and was recognised as a leading innovator by the MIT Technology Review in 2017. Beyond her business, Loubna has recently been appointed by the European Commission as a High-Level Expert on Artificial Intelligence. She will support the EU by developing recommendations on ethical, legal and societal issues related to AI, impacting the health, safety and freedom of the wider society. On a personal level, Loubna is a strong advocate for diversity and challenging the status quo. Having lived in Morocco, moving to the Netherlands at the age of 17, and later to the UK with a young family, she realised the power of remaining outside her comfort zone.
Follow Loubna Bouarfa:
About OKRA Technologies: OKRA is an AI analytics company for healthcare. We combine complex data sets, you get evidence-based insights and predictions in real time.
Martin-Immanuel Bittner
Co-Founder & CEO of Arctoris
Martin-Immanuel Bittner MD DPhil is a clinician-scientist and life sciences entrepreneur. He is a Rhodes scholar, an active member of several leading cancer research organisations, and an elected member of the Young Academy of the German National Academy of Sciences. Martin is a Co-Founder & CEO of Arctoris, the world’s first fully automated drug discovery platform.
Follow Martin-Immanuel Bittner:
About Arctoris: Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Thomas Fleming
Co-Founder & COO of Arctoris
Thomas Fleming is an award-winning chemist, cancer researcher, and SME Leader of the Royal Academy of Engineering. Tom is the Co-Founder & COO at Arctoris.
Follow Thomas Fleming:
About Arctoris: Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Sacha Carton
Co-Founder & COO of Airfinity
Sacha is co-founder & COO at Airfinity – a science information and analytics company. He is a data, tech and media entrepreneur who previously co-founded ad pepper media (FRA: APM), Adbrain (sold to NSDQ: TTD), Scala Ventures and advisory firm Ogmenta and has been an investor, advisor and director in multiple media, data, adtech, PE and M&A companies in Europe and the US.
Follow Sacha Carton:
About Airfinity, Scala Ventures: Airfinity is a science information and analytics company
Ronan Cunningham
Founder and Chief Executive Officer of BrainWaveBank
Ronan has more than 20 years of experience in advanced engineering and product development. He was one of the founding members of ATA Engineering, an award-winning San Diego-based engineering company specializing in development of innovative hardware and software technologies for the aerospace and defence industries. His roles have included Director of Business Development and Director of New Technology Development. He is an Entrepreneur-in-Residence with the Northern Ireland Science Park. His expertise is in early stage technology development, innovation strategy, and technology commercialisation. He holds an MS in Aeronautics and Astronautics from MIT.
Follow Ronan Cunningham:
About BrainWaveBank, Cumulus Neuroscience: BrainWaveBank makes it possible to measure and track brain activity and cognitive performance for anyone, anytime, anywhere.
Charlie Groome
Founder of Everna
Follow Charlie Groome:
About Everna: Everna is a biotech company developing novel therapeutics.
Shravane Balabasqer
Founder | CEO of Carbon Analytics
Follow Shravane Balabasqer:
About Carbon Analytics: A granular asset focused carbon intelligence & offsetting platform for active industrial decarbonisation across the value chain.
Jordan Van Flute
Co-Founder & CTO of Inovus Medical
Jordan is is a psychology graduate from Cardiff University. His main roll is head of the design and manufacturing team, the area in which he is the most passionate. It is his original research into psychomotor testing and laparoscopic surgery, which provided the fundamental ideas for the first Pyxus laparoscopic simulator.
Follow Jordan Van Flute:
About Inovus Medical: The perfect package for any general surgical trainees or residents.
Edward Ridyard
Co-Founder of Inovus Medical
Edward studied medicine at the University of Manchester. He played a crucial role in the early conception of the Pyxus laparoscopic simulator, liaising with surgeons and surgical trainees in order to develop a customer centred product. Although still important to the Inovus team, he has taken a step back from daily operations in order to pursue a career in surgery.
Follow Edward Ridyard:
About Inovus Medical: The perfect package for any general surgical trainees or residents.
Elliot Street
Co-Founder & CEO of Inovus Medical
Elliot studied medicine at the University of Manchester before completing his foundation training at the Oxford University Hospitals. Alongside his clinical commitments, he retains an active role in product development, bridging the gap between clinician and designer as well as running Inovus’ sales and marketing operations.
Follow Elliot Street:
About Inovus Medical, NHS England: The perfect package for any general surgical trainees or residents.
Javier Gonzalez-Zabaleta
Founder & CEO of Medimsight
Javier Gonzalez-Zabaleta was the main designer of the cloud model to bring worldwide medical imaging artificial intelligence solutions accessible to everyone. As one of the pioneers in this space, he has achieved a good experience in both market space and the technology. During last 10 years, he focused at the same time in business development, including direct communication with clinicians, and the understanding of the clinical trials market. Always open to talk, partnering and sharing knowledge. At the university, he studied computer science before made a master degree in computer vision making research in areas like multiple sclerosis and Alzheimer disease. Following his dream, empowering researchers and building super doctors, he has lived in Ponferrada, Madrid and now in London.
Follow Javier Gonzalez-Zabaleta:
About FundRx, Medimsight: Medical image triage and biomarkers analysis for precision medicine.
Nigel Dimmock
Founder of VirionHealth
Follow Nigel Dimmock:
About University of Warwick, VirionHealth: VirionHealth is a biotechnology company
Andrew Easton
Founder of VirionHealth
Follow Andrew Easton:
About University of Warwick, VirionHealth: VirionHealth is a biotechnology company
Peter Widdowson
Founder & CEO of Quethera
Peter Widdowson has over 30 years of drug discovery experience during which he has worked on a number of small molecule, protein and gene therapy approaches to managing disease. He has a background in researching therapies for indications as diverse as ophthalmic, neurological and psychiatric disorders, type-2 diabetes, oncology, gastrointestinal motility disorders and inflammatory conditions encompassing inflammatory bowel disease and rheumatoid arthritis. He has held a number of senior scientific roles within Servier (Research Group Leader), AstraZeneca (Senior Scientist and Project Research Manager), Pfizer (Senior Scientist and Project Research Manager), OSI Pharmaceuticals (Director of Pharmacology) and most recently, whilst Head of Preclinical Development at Oxford BioMedica was responsible for overseeing and managing the development of three lentiviral vector gene therapies for wet age-related macular degeneration, Stargardt disease and Usher 1B syndrome which are all currently in Phase I/II clinical development. Dr. Widdowson has experience in all aspects of preclinical and early stage development from animal model proof-of-concept studies to clinical trial design and biomarker identification. Widdowson holds a Bachelor of Science degree in human Physiology from Newcastle University and a PhD in Neuropharmacology from Manchester University.
Follow Peter Widdowson:
About Ikarovec, Quethera: Quethera is a gene therapy company dedicated to improving the future treatment of common blinding eye diseases.
Valerie Morisset
Co-Founder, EVP of R&D, and CSO of Eliem Therapeutics
Valerie Morisset is the Co-Founder, EVP of R&D, and CSO at Eliem Therapeutics.
Follow Valerie Morisset:
About Eliem Therapeutics: Eliem Therapeutics is a clinical-stage biotechnology company developing treatments for nervous system disorders.
Mark Larkin
CEO and Founder of Vitaccess
Mark Larkin founded Vitaccess in 2017, after more than 15 years in consultancy, with the aims of harnessing the power of digital technology to better represent the voice of patients in drug development and market access. Mark has a BA, MA and PhD from the University of Cambridge, UK.
Follow Mark Larkin:
About Vitaccess: Digital healthcare company providing biopharma clients with real-time insights into patients’ lives via innovative global studies
Michael McArthur
CSO and Co-Founder of Procarta Biosystems
Michael McArthur(CSO, Co-Founder) is the Professor of Nanomedicine at the Norwich School of Medicine, UEA. He is a Molecular Microbiologist with over 20 years experience of academic and biotechnology research. His defining scientific interest is how the control of bacterial genes can be used to create new antibacterials. He leads multidisciplinary research teams with expertise in: molecular biology, microbiology, chemistry, biophysical characterisation and formulation. Michael gained his PhD from University of Cambridge and has held academic positions in the EU (John Innes Centre, ICMB in Crete) and University of Washington, Seattle. Whilst there his technologies were used to found a diagnostics company, Regulome Inc, for whom he served as Director of Research. He is named on 15 patents and help raise $30m in private and grant funding.
Follow Michael McArthur:
About Procarta Biosystems: Procarta Biosystems develops antibacterials through an adaptable DNA-based platform to counter the rise of drug-resistant bacterial strains.
Sarah Gilbert
Co-Founder & Professor of Vaccinology of Vaccitech
Professor Sarah Gilbert is Professor of Vaccinology at Oxford University and the programme director for a Wellcome Trust Strategic Award on Human and Veterinary vaccines at the Jenner Institute. She is a member of the Oxford University Clinical Biomanufacturing Facility management committee, and an acknowledged expert in the preclinical and clinical development of viral vectored vaccines.Professor Gilbert’s chief research interest is the development of vaccines that work by inducing strong and protective T cell responses, in addition to working on the development of the viral vector platform technology and its application in rapid vaccine development for emerging pathogens.
Follow Sarah Gilbert:
About Vaccitech: Vaccitech is creating novel vaccines that elicit strong responses from helper and cytotoxic T-cells.
Nativ Segev
Managing Director & Co Founder of MGC Pharmaceuticals
Nativ Segev is the Founder and Director of MGC Pharmaceuticals Ltd.
Follow Nativ Segev:
About MGC Pharmaceuticals: MGC Pharmaceuticals is a company founded with vision. A vision of globalizing the arena in which Cannabis, and specifically CBD.
Jane Osbourn
Co-Founder, Chief Scientific Officer & Chief Technology Officer of Alchemab Therapeutics
Jane Osbourn is the chairman at Mogrify.
Follow Jane Osbourn:
About Alchemab Therapeutics: Alchemab Therapeutics is developing natural protective antibodies designed to keep people free of hard-to-treat diseases.
Neal L Millar
Co Founder & CMO of Causeway Therapeutics
Neal is an Academic Consultant Orthopaedic Surgeon specialising in shoulder surgery having completed fellowships in Sydney and New York and is an expert in human tendinopathy.
Follow Neal L Millar:
About Causeway Therapeutics, University of Glasgow, University of Glasgow: A bio pharmaceutical spin out emerging.
Derek Gilchrist
Co Founder & CEO of Causeway Therapeutics
Derek is a principal investigator at the University of Glasgow and leads the scientific and technical development of TenoMiR™.
Follow Derek Gilchrist:
About Causeway Therapeutics, University of Glasgow, University of Glasgow: A bio pharmaceutical spin out emerging.
Duncan Hall
Founder and CEO of Triumph Research Intelligence
Duncan has over fifteen years of consultancy experience, thirteen of which have been within clinical R&D in both CRO and Pharma businesses. Duncan started Triumph in 2002 with the aim of building a global business which would be focused in improving the delivery, quality and value of clinical systems. Duncan now takes a primarily strategic role in TRI, but still performs client delivery roles where possible.
Follow Duncan Hall:
About Triumph Research Intelligence: Triumph Research Intelligence is a risk-Based Monitoring Company.
Idlir Liko
Co-Founder & CTO of OMass Technologies
Idlir Liko is currently the founder and Technology Director of OMass Therapeutics. He received a Master’s Degree from ETH Zurich in 2012 and DPhil from the University of Oxford in 2015, supervised by Prof. Dame Carol Robinson where he focused on the effect ligands and PTMs have on structure and stability of membrane proteins. His work was been featured in many high-impact publications. He has a wealth of experience in structural MS working in close collaboration with biotech and pharmaceutical companies. In 2016, he co-founded the company and has played a key role in transferring our technology from academia to industry.
Follow Idlir Liko:
About OMass Technologies: OMass Technologies is a drug discovery company exploiting novel mass spectrometry platforms to develop therapeutics.
Malcolm Weir
Founder & CEO of Heptares Therapeutics
Former Visiting Professor of Biochemistry at Imperial College, London. Former Head of the Molecular Sciences Division of Glaxo Wellcome Inc. (present Glaxo Smithkline plc.) Former CEO of Inpharmatica Ltd.（present Galapagos NV). Founder and CEO of Heptares Therapeutics Ltd.
Follow Malcolm Weir:
About Heptares Therapeutics, Sosei Group: Heptares Therapeutics develops novel, small-molecule drugs for G-protein-coupled receptors (GPCRs).
Allison Jeynes-Ellis
Co-Founder & CEO of Avillion
Over 20 years of senior leadership experience in the pharmaceutical industry. Significant global drug development experience and successful EU and US drug approvals across a range of therapeutic areas. Leadership of global clinical development teams for Phase 3, including CRO selection and management. Strong networks within the pharma industry and relevant regulatory bodies
Follow Allison Jeynes-Ellis:
About Avillion: Avillion LLP, a London, UK-based company that focuses on clinical co-development of therapeutics.
Paul Townsend
Founder of Karus Therapeutics
Paul Townsend is Founder at Karus Therapeutics.
Follow Paul Townsend:
About Aptamer Group, Deep Med IO, Karus Therapeutics, Manchester Cancer Research Centre, University of Surrey: Karus is a pharmaceutical company focused on the design and development of molecular-targeted, small molecule drugs to treat cancer.
Guang Zhong Yang
Co-Founder of Smart Surgical Appliances
Guang-Zhong Yang is Founder of Smart Surgical Appliances Limited. Guang-Zhong Yang serves at Institute of Biomedical Engineering.
Follow Guang Zhong Yang:
About Smart Surgical Appliances: Smart Surgical Appliances is a medical device company, developing sensor-enabled surgical instrumentation.
Ara Darzi
Co-Founder of Smart Surgical Appliances
Prof. Ara Darzi, KBE MD, FRCS, FRCSI, FACS, co-founded SynaptiQ Ltd. in 2001. Prof. Darzi is the Founder of Smart Surgical Appliances Limited. He serves as the Head of Scientific Advisory Board, Director and Member of Scientific Advisory Board of SynaptiQ Ltd. He served as a Hunterian Professor of the Royal College of Surgeons of England. He holds the Chair of Surgery at Imperial College School of Medicine and is also the Tutor in Minimal Access Surgery at the Royal College of Surgeons in England. He is the James IV traveling fellow for 1999/2000, and is also a Council Member of the Association of Coloproctologists of Great Britain and Ireland, The Association of Endoscopic Surgeons of Great Britain and Ireland, and the Society of Minimal Invasive Therapy. He is also the Chairman of the London Committee for the Modernisation of the National Health Service, which is charged with recommending how best to modernise the NHS. He was appointed as Advisor on Surgery to the Department of Health. He serves as Vice Chairperson at Sidra Medical and Research Centre. He conferred a Fellow of the American College of Surgeons. His main clinical and academic interest is Minimal Invasive Therapy, including Imaging and Biological research. He has co-authored over 100 peer review publications and five books on surgery. Prof. Darzi received an honorary Knighthood in December 2002 in recognition of his service to the United Kingdom National Health Service. Prof. Darzi obtained his fellowship in Surgery from the Royal College of Surgeons in Ireland and an M.D. degree from Trinity College, Dublin.
Follow Ara Darzi:
About Smart Surgical Appliances, The Institute of Cancer Research: Smart Surgical Appliances is a medical device company, developing sensor-enabled surgical instrumentation.
Matt Baker
Co-Founder of Foundry³
Follow Matt Baker:
About Foundry³: Foundry3 is a corporation that focuses on science, creativity, and innovation to help shape the future of healthcare.
Gordon McInroy
Founder and CTO of Nuclera
Follow Gordon McInroy:
About Nuclera: Nuclera makes biology accessible through desktop enzymatic protein and gene synthesis.
Peter Kennerley
Chief Executive Officer & Founder of Emas Pharma
Peter joined the pharmaceutical industry in 1987 after several years in the NHS as an anaesthetist. Since then, he has worked in senior positions for major as well as small Pharma companies, with duties ranging from drug development to medical affairs and he has brought several products to market, both as blockbusters and as niche products. Since establishing Emas, he has chaired expert panels, established drug safety processes and overseen successful regulatory procedures for a range of products from radiolabelled monoclonal antibodies to mast cell histamine release inhibitors and from glucoside inhibitors to proton pump inhibitors. He retains a determination that Emas should avoid the usual service company clichés and simply demonstrate its worth through the highest possible quality support at a competitive cost.
Follow Peter Kennerley:
About Emas Pharma: Emas Pharma provides pharmaceutical and device development services worldwide and specializes in partnering with specialist pharma.
Dan Hydes
CEO & Co-Founder of IgniteData
Follow Dan Hydes:
About IgniteData: IgniteData is the company shaping the future of clinical trials through its innovative digital health platform, Archer.
Michael O’Neill
Co-Founder and Director R&D of Inflection Biosciences
Michael O’Neill has more than 20 years’ experience working in the pharmaceutical industry. He was a Senior Research Scientist and Portfolio Manager at Eli Lilly for much of this time where he was responsible for developing project plans for the selection of projects and for their progression from discovery through to important development milestones. He established his own consulting business, Eolas, to help early stage companies to organize their research along commercial lines, becoming accomplished at building highly streamlined development plans. He has built consortia of commercial and academic groups to apply for major EU grants. Previously Dr. O’Neill was Head of Laboratory at Almirall and a Research Neuroscientist at Merck. He has authored over 80 papers, book chapters, patents and abstracts and is Honorary Visiting Senior Lecturer at the Science Policy Research Unit at the University of Sussex. He holds a BA Psychology from UCC and a PhD from QUB Belfast.
Follow Michael O’Neill:
About Inflection Biosciences: Inflection Biosciences is a company that develops small-molecule therapeutics for the treatment of cancer.
Jeff Moore
Founder & CEO of Curileum Discovery Ltd
Follow Jeff Moore:
About Curileum Discovery Ltd: Curileum Discovery Ltd is a drug target discovery company in London targeting defective stem cells underpinning serious GI diseases
STEVE HOLMES
CEO and Founder of Capella BioScience
Follow STEVE HOLMES:
About Capella BioScience: Capella Bioscience engages in the discovery and development of monoclonal antibodies.
Tim Venison
Co Founder of Spotlight Data
Follow Tim Venison:
About Hotswell Ltd., Spotlight Data: Spotlight Data – Strategic KM Ltd. Is an artificial intelligence data company working the UK Government and multi nationals
Daljit Cheema
Founder & CEO of PHARMASEAL
Daljit Cheema is Founder & CEO at PHARMASEAL.
Follow Daljit Cheema:
About PHARMASEAL: PHARMASEAL is developing the first B2B control platform for biopharmaceutical companies to manage their enterprise clinical trials.
Joanne Taylor
Founder of Life Science Leaders
Follow Joanne Taylor:
About Life Science Leaders: Life Science Leaders is an executive search company that specializes in the life science and medical industries.
Hakim Yadi
CEO & Co-Founder of Closed Loop Medicine
Hakim Yadi is the CEO and Co-Founder at Closed Loop Medicine.
Follow Hakim Yadi:
About : Developing personalised digital healthcare solutions to improve outcomes for patients and clinicians
Dominic Miller
Chief operating officer & Co-Founder of Fishawack
Dominic Miller has been serving as chief operating officer of Fishawack since February 2001.
Follow Dominic Miller:
About Fishawack: Fishawack provides fully-integrated, cross-border services to global pharmaceutical organisations.
Oliver Dennis
Chief executive officer & Co-Founder of Fishawack
Oliver Dennis has been chief executive officer of Fishawack since January 2010.
Follow Oliver Dennis:
About Fishawack: Fishawack provides fully-integrated, cross-border services to global pharmaceutical organisations.
Alfredo Boni
Founder & President of Creabilis
Alfredo Boni was the CEO of a large service company, Boni S.p.A, which has operated since 1964 across Europe within many industries in the field of general maintenance, cleaning and sterilization. He was also the founder of a consortium of more than 150 companies devoted to global service for various institutions including hospitals. His industrial, financial and administrative experience in founding and acquiring companies and his entrepreneurial spirit are now being devoted to the world of biotechnology.
Follow Alfredo Boni:
About Creabilis: Creabilis, a specialty pharmaceutical company focused on dermatology, discovers and develops new medicines for a range of skin disorders.
Adam Perriman
Founder and CSO of Cytoseek
Follow Adam Perriman:
About Cytoseek: For next-generation cell therapies.
Ian Harrison
Founder & CSO of Alchemy Pharmatech
Ian Harrison is a Founder & CSO at Alchemy Pharmatech.
Follow Ian Harrison:
About Alchemy Pharmatech: Alchemy Pharmatech is an innovation-driven company developing drug delivery platforms in partnership with the pharmaceutical industry.
Andrew Hook
Founder & CEO of Tracepad
Follow Andrew Hook:
About Tracepad: Tracepad develops innovative solutions for pharmaceutical provenance.
Tariq Aslam
Founder of Clin-e-cal
Follow Tariq Aslam:
About Clin-e-cal: Clin-e-cal is a digital health company,
Boo Virk
Founder of Magnitude Biosciences
Follow Boo Virk:
About Magnitude Biosciences: Magnitude Biosciences is a biotechnology firm combine experience in ageing research, the nematode C. elegans and automation.
John Dawson
CEO & Founder of Alliance Pharmaceuticals
Follow John Dawson:
About Alliance Pharmaceuticals: Alliance’s principal activities are the acquisition and licensing of mature pharmaceutical products and the marketing of those products.
